{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:34:40Z","timestamp":1762853680579,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.oret.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T21:39:04Z","timestamp":1656106744000},"page":"1154-1164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing Early Residual Fluid in Neovascular Age-Related Macular Degeneration using Machine Learning in Routine Clinical Practice"],"prefix":"10.1016","volume":"6","author":[{"given":"Anna K.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott W.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2022.06.006_bib1","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2022.06.006_bib2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2022.06.006_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib7","article-title":"Fluctuations in retinal thickness in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents","volume":"61","author":"Chen","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.06.006_bib8","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2022.06.006_bib9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2021.06.029","article-title":"Effect of residual retinal fluid on visual function in ranibizumab-treated neovascular age-related macular degeneration","volume":"233","author":"Holekamp","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib12","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","article-title":"Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post hoc analyses from the ALTAIR study","volume":"259","author":"Ohji","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajo.2021.10.017","article-title":"Early residual fluid-free status and long-term BCVA outcomes: a treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data","volume":"236","author":"Jhaveri","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib14","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2012.06.056","article-title":"Predictors of AMD treatment response","volume":"119","author":"Wickremasinghe","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256461","article-title":"Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: results from the EAGLE study","volume":"16","author":"Staurenghi","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.oret.2022.06.006_bib16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","article-title":"Automated identification of lesion activity in neovascular age-related macular degeneration","volume":"123","author":"Chakravarthy","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib17","unstructured":"M. Goldstein, M. Havilio, O. Rafaeli, et al., American Academy of Ophthalmology Annual Meeting; Oct 12-15, 2019. San Francisco, CA."},{"key":"10.1016\/j.oret.2022.06.006_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","article-title":"Retinal Specialist versus artificial intelligence detection of retinal fluid from OCT: Age-Related Eye Disease Study 2: 10-year follow-on study","volume":"128","author":"Keenan","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","article-title":"Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","article-title":"Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration","volume":"33","author":"Brown","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/aos.14786","article-title":"Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study","volume":"99","author":"Saenz-de-Viteri","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.oret.2021.06.003","article-title":"Predominantly persistent subretinal fluid in the comparison of age-related macular degeneration treatments trials","volume":"5","author":"Core","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib24","first-page":"97","article-title":"Relationship between intraretinal and subretinal fluid with visual acuity in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor","volume":"62","author":"Iyer","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.06.006_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ophtha.2017.12.034","article-title":"Predicting visual acuity by using machine learning in patients treated for neovascular age-related macular degeneration","volume":"125","author":"Rohm","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.oret.2017.03.015","article-title":"Machine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degeneration","volume":"2","author":"Schmidt-Erfurth","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","article-title":"Machine learning can predict anti\u2013VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema","volume":"5","author":"Gallardo","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ophtha.2020.08.031","article-title":"Predicting progression to advanced age-related macular degeneration from clinical, genetic, and lifestyle factors using machine learning","volume":"128","author":"Ajana","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.06.006_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00417-017-3839-y","article-title":"OCT-based deep learning algorithm for the evaluation of treatment indication with anti-vascular endothelial growth factor medications","volume":"256","author":"Prahs","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2022.06.006_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.06.006_bib31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2022.06.006_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302200313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302200313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:30:55Z","timestamp":1762853455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302200313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S246865302200313X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2022.06.006","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing Early Residual Fluid in Neovascular Age-Related Macular Degeneration using Machine Learning in Routine Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}